A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

Last updated:
2026-09-12
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

FRAMEWORK-01: A TWO-PART PHASE 3 STUDY OF LY4170156 VERSUS CHEMOTHERAPY OR MIRVETUXIMAB SORAVTANSINE IN PLATINUM-RESISTANT OVARIAN CANCER, AND LY4170156 PLUS BEVACIZUMAB VERSUS PLATINUM-BASED CHEMOTHERAPY PLUS BEVACIZUMAB IN PLATINUM-SENSITIVE OVARIAN CANCER

Intervention/treatment:
LY4170156 / BEVACIZUMAB / PACLITAXEL / DOXORUBICIN HYDROCHLORIDE / GEMCITABINE HYDROCHLORIDE / TOPOTECAN / CARBOPLATIN
Medical condition:
OVARIAN CANCER
Protocol code:
J5E-MC-JZXB
Control number:
303735
Status:
Recruiting
Approved:
December 19, 2025
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT07213804
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Trial questions or participation questions 1-877-CTLILLY (1-877-285-4559) or
Role
CONTACT
Phone:
1-317-615-4559
Name
Physicians interested in becoming principal investigators please contact
Role
CONTACT
Sponsor
ELI LILLY CANADA INC

Locations

Arthur J.E. Child Comprehensive Cancer Centre
Calgary, T2N 5G2
NOT_YET_RECRUITING
Role
CONTACT
Phone:
4025213721
Name
Prafull Ghatage
Role
PRINCIPAL_INVESTIGATOR
BC Cancer Surrey
Surrey, V3V 1Z2
NOT_YET_RECRUITING
Role
CONTACT
Phone:
604-587-4314
Name
Aalok Kumar
Role
PRINCIPAL_INVESTIGATOR
Centre intégré universitaire de santé et de services sociaux de l'Estrie Centre Hospitalier Universitaire -T
Sherbrooke, J1H 5N4
NOT_YET_RECRUITING
Role
CONTACT
Phone:
8193461110 x 12890
Name
Paul Bessette
Role
PRINCIPAL_INVESTIGATOR
Hamilton Health Sciences-Juravinski Cancer Centre
Hamilton, L8V5C2
NOT_YET_RECRUITING
Name
Nidhi Kumar Tyagi
Role
PRINCIPAL_INVESTIGATOR
Jewish General Hospital
Montreal, H3T 1E2
NOT_YET_RECRUITING
Name
Susie Lau
Role
PRINCIPAL_INVESTIGATOR
Princess Margaret Cancer Centre
Toronto, M5G 2M9
RECRUITING
Name
Amit Oza
Role
PRINCIPAL_INVESTIGATOR
Sunnybrook Research Institute
Toronto, M4N 3M5
NOT_YET_RECRUITING
Role
CONTACT
Phone:
4164805000x4026
Name
Lilian Gien
Role
PRINCIPAL_INVESTIGATOR
Did you find what you were looking for?